3B Films IPO share allotment in focus today; GMP, how to check status in 4 steps
The company is to finalise share allotment today, Wednesday, Jun 4. Successful bidders can expect the shares to be credited to their demat accounts on Thursday, Jun 5. Those who do not receive an allotment will receive refunds on the same day. The stock may debut on the BSE SME on Friday, June 6.
Investors who bet on the IPO can check the share allotment status online on the registrar's website. They can also check the share allotment status on the official websites of the BSE.
Maashitla Securities Private Limited is the official registrar of the SME IPO.
One can follow these steps to check the share allotment status:
Step 1: Visit the registrar's website with this direct weblink
Step 2: Select '3B Films IPO' from the "select company" dropdown
Step 3: Select either 'PAN, Application No., or Demat Account' and fill in the details
Step 4: Click on the 'Submit' button.
Your 3B Films IPO allotment status will appear on your computer monitor or mobile phone screen.
To check 3B Films IPO allotment status online on the BSE website, one needs to log in at the direct BSE link and follow the below-mentioned step-by-step guide:
Step 1: Log in to the BSE link — bseindia.com/investors/appli_check.aspx
Step 2: Select 'Equity' in the issue type option
Step 3: Select '3B Films'
Step 4: Fill in the application number or PAN card details in the given space
Step 5: Click on 'I'm not a robot' and
Step 6: Click on the 'Search' option.
Your 3B Films IPO allotment status will appear on your computer monitor or mobile phone screen.
According to market sources, the last grey market premium (GMP) of the stock was zero. This indicates the stock could be listed at par on the BSE SME.
Read all market-related news here
Disclaimer: The views and recommendations above are those of individual analysts, experts, and brokerage firms, not Mint. We advise investors to consult certified experts before making any investment decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
27 minutes ago
- Business Standard
Torrent Pharma bucks weak market trend; rallies 3%, hits record high
Torrent Pharma Q1FY26 results on Monday, July, 28, 2025: In past one month, the stock has outperformed by surging 12%, as compared to 1.4% decline in the Sensex and 4% rise in the BSE Healthcare index Torrent Pharma share price today Shares of Torrent Pharmaceuticals hit a record high of ₹3,612.20, as they rallied 3 per cent on the BSE in Friday's intra-day trade in an otherwise weak market. The stock price of the pharmaceutical company surpassed its previous high of ₹3,589.95 touched on October 10, 2024. In comparison, the BSE Sensex was down 0.74 per cent at 81,579 at 01:59 PM. In the past one month, Torrent Pharmaceuticals has outperformed the market by surging 12 per cent. In comparison, the BSE Sensex was down 1.4 per cent, while, BSE Healthcare index gained 4 per cent during the period. CATCH STOCK MARKET LIVE UPDATES TODAY Q1FY26 results on Monday, July, 28, 2025 The board of directors of Torrent Pharmaceuticals will meet on Monday, July 28, 2025 to consider and approve the audited financial results of the company for the quarter ended on June 30, 2025 (Q1FY26). Torrent - JB Chemicals Pharmaceuticals (JBCP) deal On June 29, 2025, Torrent Pharmaceuticals announced a major strategic move with the acquisition of a controlling 46.4 per cent stake in JB Chemicals & Pharmaceuticals (JBCP) for ₹11,920 crore at ₹1,600 per share from the promoter Tau Investment Holdings or KKR. In addition, the company launched an open offer for a further 26 per cent at ₹1,639.18 per share and intends to merge JBCP within itself through a court-approved scheme. This represents Torrent Pharma's largest-ever acquisition and positions it as a stronger firm in India's branded generics landscape, with deeper reach across therapeutic areas and geographies. Torrent's deep India presence and JBCP's fast growing India business, combined with the Contract Development and Manufacturing Organization (CDMO) and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers Torrent's goal of strengthening the company's presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent. The combined entity would operate at ₹15,400 crore revenue base with a broader branded portfolio and expanded international presence. While the acquisition premium is steep, long-term value creation hinges on efficient integration, synergy realization, and sustained growth across domestic and global businesses, according to analysts at Elara Capital. Way Forward Moving ahead, Torrent Pharma in its FY25 annual report said that the company's focus will be on consolidating and strengthening its leadership position in the branded generic segment. In India, the company will focus on strengthening its leadership in key therapy areas, expanding consumer health portfolio, and enhancing field force productivity to capture untapped opportunities. In the international markets, the company anticipates continued growth in Brazil, driven by recent successful launches and a robust pipeline awaiting regulatory approvals. In Germany, new tender wins are expected to support revenue growth despite some challenges in the OTC segment. The US market remains stable, with a focus on maintaining compliance and a strong product pipeline, the company said. India-UK Free Trade to benefit pharma companies The India-UK Free Trade Agreement is set to boost India's pharma Industry by expanding market access for generics and biosimilars, fast-tracking approvals, and encouraging cross-border R&D. It also enables collaborations in bulk drug imports and CDMO. While most pharma exports to the UK were already duty-free, the UK's commitment to zero tariffs on 99 per cent of exports formalises this, offering long-term clarity. Pharma exports to the UK stood at ~US$910 million in FY24, ICICI Securities said in a note.
Mint
27 minutes ago
- Mint
Cipla Q1 PAT rises 10 pc to ₹1,298 cr; income at ₹6,957 cr
New Delhi, Jul 25 (PTI) Drug major Cipla on Friday reported a 10 per cent increase in its consolidated profit after tax to ₹ 1,298 crore for the first quarter ended June 30, 2025, aided by robust sales growth in India, Europe, and Africa. The company had posted a profit after tax (PAT) of ₹ 1,178 crore for the April-June quarter of the previous fiscal. Total Income from operations rose to ₹ 6,957 crore for the June quarter as compared with ₹ 6,694 crore in the year-ago period, Cipla said in a statement. Cipla MD and Global CEO Umang Vohra said the company's One-India business grew at 6 per cent year-on-year during the quarter. Key therapies in the branded prescription business continued to outpace the market growth, trade generics business growth trajectory is back on track and anchor brands of consumer health business maintained leadership position, Vohra stated. "Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front," Vohra said. The company said its sales in the Indian market rose to ₹ 3,070 crore for the first quarter, an increase of 6 per cent as compared with ₹ 2,898 crore in the year-ago period. North America sales declined 7 per cent year-on-year to ₹ 1,933 crore for the June quarter. Emerging markets and Europe saw sales at ₹ 861 crore for the first quarter, a growth of 11 per cent as against ₹ 779 crore in the year-ago period. Africa sales grew 14 per cent year-on-year to ₹ 871 crore for the June quarter as compared with ₹ 766 crore in the April-June period of last year. Cipla shares were trading 3.8 per cent up at ₹ 1,543.80 apiece on BSE.
Mint
27 minutes ago
- Mint
Monarch Surveyors IPO allotment date in focus. Latest GMP, steps to check share allotment status online of SME IPO
Monarch Surveyors IPO Allotment: The initial public offering (IPO) of civil engineering consultancy company, Monarch Surveyors & Engineering Consultants Ltd, received exceptional demand. As the bidding has ended, investors watch out for Monarch Surveyors IPO date, which is expected to be fixed soon. The public issue was open from July 22 to 24. Monarch Surveyors IPO allotment date is likely today, 25, July 2025, Friday. Whereas, Monarch Surveyors IPO listing date is expected to be July 29. As the issue is an SME IPO, the equity shares of the company will be listed on BSE SME. The company is expected to finalise the Monarch Surveyors IPO allotment status soon. Once the Monarch Surveyors IPO allotment is fixed, the company will then credit the equity shares into the demat accounts of eligible allotment holders, and initiate refund on the same day. Investors can check Monarch Surveyors IPO allotment status online through the BSE website or the official portal of IPO registrar. Bigshare Services Pvt Ltd is the IPO registrar. In order to do Monarch Surveyors IPO allotment status online check, investors must follow of a few simple steps mentioned below: Step 2] Select 'Equity' in the Issue Type Step 3] Choose 'Monarch Surveyors & Engineering Consultants Limited' in the Issue Name dropdown menu Step 4] Enter either Application No. or PAN Step 5] Verify by ticking on 'I am not robot' and click on 'Search' Your Monarch Surveyors IPO allotment status will be displayed on the screen. Step 1] Visit the web portal of Bigshare Services here - Step 2] Select 'Monarch Surveyors & Engineering Consultants Limited' in the Select Company dropbox Step 3] Choose among - Application Number/CAF No, Beneficiary ID, or PAN Step 4] Enter the details as per the option selected Step 5] Fill the captcha and hit on 'Search' Your Monarch Surveyors IPO allotment status will be displayed on the screen. Monarch Surveyors shares are available at a strong grey market premium (GMP) today. According to market experts, Monarch Surveyors IPO GMP today is ₹ 210 per share. Monarch Surveyors IPO GMP today indicates that the estimated listing price of the equity shares would be ₹ 460 apiece, which is at a premium of 84% to the issue price of ₹ 250 per share. The bidding for Monarch Surveyors IPO commenced on July 22, and concluded on July 24. Monarch Surveyors IPO allotment date is likely today, 25 July 2025, and the Monarch Surveyors IPO listing date is likely July 29. The equity shares of the company will be listed on BSE SME. Monarch Surveyors IPO price band was fixed at ₹ 250 per share. The company raised ₹ 93.75 crore from the issue which was entirely a fresh issue of 37.50 lakh shares. The public issue received strong subscription, led by stellar demand across categories. Monarch Surveyors IPO was subscribed 250.65 times in total as the issue received bids for 62.20 crore equity shares as against 24.81 lakh shares on the offer. The IPO was subscribed 263.01 times in the individual investors category, 179.01 times in the Qualified Institutions Buyers (QIB)segment, and 317.05 times in the Non-Institutional Investors (NII) category. Beeline Capital Advisors Pvt Ltd is the book-running lead manager of the Monarch Surveyors IPO, while Bigshare Services Pvt Ltd is the IPO registrar. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
